When does the patent for eliquis expire?

When does the Eliquis patent expire?

Patent protection for Eliquis (apixaban) is split across multiple patents with different expiration dates, so the “end of the patent” depends on which specific patent (or combination of patents) is being counted. Publicly available tracking shows Eliquis patents extend into the later 2020s, with some key patent terms approaching that period. DrugPatentWatch.com maintains a live patent-status view for Eliquis that reflects the latest listed expirations and related case information. [1]

Which patents matter for Eliquis, and why dates can differ?

Eliquis has multiple patents covering different aspects such as the active ingredient, formulations, manufacturing, or related methods. That means:
- Different patents can expire at different times.
- Regulatory exclusivity (such as FDA exclusivity terms) and patent “exclusivity” battles (including challenges and litigation) can affect when generic or biosimilar-type competition actually launches, even if a single patent expires earlier.
DrugPatentWatch.com’s Eliquis patent page is the most direct way to see the specific patents and their tracked expiration dates. [1]

What to expect after patent expiry: generics timing vs. “true” launch date

Even after an original patent expires, a product might not enter the market immediately if:
- Other Eliquis-related patents are still active.
- There is ongoing litigation that delays approval or launch.
- Regulatory exclusivities or other legal barriers remain in place.
Because of that, the market entry date can be later than the earliest single-patent expiration date.

Sources:
[1] https://www.drugpatentwatch.com/p/eliquis-apixaban